Zhongshan Hospital Cardiac Surgery: Valve, Coronary and Aortic Teams

What the hospital record establishes, and what it does not

Zhongshan Hospital is a Fudan University-affiliated comprehensive public hospital in Shanghai. A Fudan University report marking its 80th anniversary, published on 17 September 2017, records that it opened on 1 April 1937 and that its work combines clinical care, research, teaching and management under a public-hospital mission. The same anniversary account describes academic exchange in the cardiovascular, liver, kidney and pulmonary fields.

That is institutional history, not a current description of bed numbers, staffing or service availability. Older figures from anniversary coverage should not be read as today's capacity. For a patient, the useful point is narrower: cardiac surgery sits inside a large academic hospital where several specialties work alongside each other, which matters when a heart operation depends on imaging, anaesthesia, intensive care and kidney expertise at the same time.

One dated reference is worth knowing. The hospital's cardiac surgery specialty appears at position 3 in the 2023 national specialty reputation list compiled by the Fudan Hospital Management Institute. Treat that as a historical, dated reference for the department as a whole. It does not rank subspecialties, does not rank individual surgeons, and is not a current 2026 ranking or a statement that any particular operation is the right choice for you.

Robotic coronary surgery: the 2014 technique account

A Fudan University report dated 28 April 2014 describes pioneering work in robotic coronary surgery. Professor Wang Chunsheng and Wei Lai, then an associate chief physician, led beating-heart robotic coronary anastomosis. The report traces how the team's bypass technique developed from robotic harvesting of the internal mammary artery toward a fuller robotic workflow, with collaboration from anaesthesia and echocardiography.

Read this as a 2014 account of technique development, not as evidence that every eligible patient today can or should have a robotic operation. Coronary surgery decisions turn on the pattern of disease, the heart's pumping function, other illness and the anatomy of the vessels. Whether a robotic or minimally invasive route is appropriate, and whether it is available for a particular case, is a clinical judgement the treating team must make and explain.

The practical question for an overseas patient is not 'can you do robotic surgery' in the abstract. It is whether the team would recommend a robotic approach for your specific coronary anatomy, what the alternative open operation would involve, and what the team's own current experience and selection criteria are.

Complex valve disease and the multidisciplinary assessment

A clinical report published by Fudan University on 13 December 2023 describes Wang Chunsheng and Wei Lai, both identified as chief physicians, working with a team on complex combined aortic, mitral and tricuspid regurgitation. The account emphasises multidisciplinary collaboration across imaging and anaesthesia, and describes an illustrative combined assessment involving transcatheter aortic valve replacement, transcatheter edge-to-edge mitral repair and tricuspid valve intervention.

That combination is an example of technical assessment in a complex case, not a standard plan for all patients with valve disease. It is also not a statement about regulatory approval or availability of any particular device or brand, in China or elsewhere. Catheter-based and open surgical options each carry their own risks and suit different anatomies and risk profiles.

For a patient with more than one affected valve, the questions worth asking are concrete. Which valves does the team consider treatable, and by which route? What imaging has been done, and what further imaging would the team want? If a catheter approach is proposed, what does the team explain about its risks and about the open-surgery alternative? The answers belong to the treating clinicians, not to a general article.

Aortic dissection research and the younger clinical-research group

A Fudan University report dated 21 April 2026 profiles Chen Jinmiao, identified as an attending physician in cardiac surgery, an associate investigator and a master's mentor, and a recipient of the 12th Fudan Top Ten Medical Youth honour. Chen's mentors are named as Hong Tao and Wang Chunsheng. The research described links Wang Chunsheng, Wei Lai and an external collaborator, Zhang Hongjun of the Lingang National Laboratory, to work on circadian mechanisms and aortic dissection.

The same report describes work with Chen Renjie on public-health associations between environmental temperature and health. That is a population-level association, not proof that temperature causes an individual's dissection. Chen is also described as a principal writer of a consensus on tricuspid regurgitation after left-sided valve surgery, and as having research on atrial functional mitral regurgitation cited in the 2025 ESC/EACTS guideline. A double-orifice mitral bioprosthesis model and related clinical research are described as research, not as a generally approved service.

Roles matter here. An attending physician and associate investigator is a clinician-researcher, not the department chief, a professor or the surgeon who will necessarily lead an operation. Naming a researcher in an article is not a referral, and it does not establish that the person sees overseas patients or holds a particular clinic.

Perioperative kidney protection: the 2024 randomised study

A Fudan University report dated 22 November 2024 describes a prospective, double-blind, randomised study of 509 cardiac surgical patients published in Circulation. It compared delayed remote ischaemic preconditioning with a control group for the risk of postoperative acute kidney injury. The authors spanned departments: Ding Xiaoqiang, nephrology chief, and Wang Chunsheng, cardiac surgery chief, with Luo Zhe, cardiac intensive care chief, as co-corresponding authors; Jia Ping in nephrology and Ji Qiang in cardiac surgery were co-first authors.

The study's value for patients is the way it shows organ protection as a shared problem. Kidney injury after heart surgery is a recognised concern, and this trial tested one preventive strategy rather than establishing a routine. Nothing in the report tells a patient to inflate a blood-pressure cuff, follow a timing protocol, or expect a particular outcome. It is not stem-cell or regeneration research.

If you have existing kidney disease, diabetes or other risk factors, ask the surgical and intensive-care teams how they assess renal risk, what monitoring they plan, and what they would do if kidney function changed after surgery. Those are questions for the clinicians who will actually manage your case.

Surgical engineering, mentorship and what honours do and do not mean

A Fudan University feature dated 6 June 2019 describes a utility model for a multifunction cardiac suture organizer, developed by Wang Chunsheng's team and licensed. It addresses how sutures are organised and counted during an operation. A separate endoscopy pathology specimen box from Zhong Yunshi's team is also described as licensed; it is not a cardiac valve invention. This is surgical workflow engineering and intellectual-property transfer, not drug or device regulatory approval, and it does not by itself prove better patient outcomes.

A report dated 3 July 2025 on university graduates describes Wang Chunsheng as a cardiac surgery professor and doctoral mentor, with clinical-research training in vascular smooth-muscle proliferation mechanisms. The student featured, Liu Fangyu, was a 2025 doctoral graduate entering thoracic cardiovascular residency; the National Scholarship and Outstanding Student Cadre awards described in that section belong to Liu, not to Wang. Research teaching and experimental work carry uncertainty and are not validated treatments.

Honours and mentorship describe academic standing. They do not predict how your operation will go, and they do not replace a consultation in which your own records are reviewed.

Practical questions before you plan care, and how coordination can help

Start with your own records: recent echocardiography, coronary angiography or CT angiography, cardiac function assessment, blood tests including kidney function, and a clear list of medicines and allergies. Ask the treating team which of these they need in a specific format, and whether any further imaging would be required before a decision. Do not stop or change any medicine on your own; that is a prescribing decision for your clinician.

Then ask direct questions. Which operation or catheter procedure would the team recommend for my anatomy, and why? What are the alternatives, including doing nothing or delaying? What does the team explain about the risks I personally face? Who would perform the operation, and what is that team's current experience with my type of case? What is the plan for intensive care, kidney monitoring and follow-up after discharge? Hospital acceptance and suitability are decided by the hospital, not by an enquiry service.

ChinaSpecialistCare can independently coordinate a cardiac surgery assessment, including record transmission, appointment arrangements and interpretation, without being the hospital's representative or guaranteeing acceptance. An initial enquiry is free and needs only a brief summary; the hospital and its clinicians decide suitability, the treatment plan and the fee scope in writing.

Heart surgery in China for international patients